Indications for: TRULICITY

As adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). To reduce the risk of major cardiovascular (CV) events (eg, CV death, non-fatal MI or non-fatal stroke) in adults with T2DM who have established CV disease or multiple CV risk factors.

Limitations of Use:

Not studied in patients with history of pancreatitis. Not for treating type 1 diabetes mellitus. Not recommended in patients with severe GI disease (including severe gastroparesis).

Adult Dosage:

Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥18yrs: initially 0.75mg once weekly; may increase to 1.5mg once weekly if inadequate response. If additional glycemic control is needed: increase to 3mg once weekly after ≥4 weeks on the 1.5mg dose; increase to max 4.5mg once weekly after ≥4 weeks on the 3mg dose.

Children Dosage:

<18yrs: not recommended.

TRULICITY Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Boxed Warning:

Risk of thyroid C-cell tumors.

TRULICITY Warnings/Precautions:

Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Monitor renal function when initiating or escalating dose, and in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.

TRULICITY Classification:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

TRULICITY Interactions:

Concomitant insulin: administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.

Adverse Reactions:

Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.

Generic Drug Availability:


How Supplied:

Single-dose pen—4

Pricing for TRULICITY

4 pens of 0.75mg/0.5ml carton (Qty: 1)
Appx. price $878